Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Activating mutations in one of the two subunits of the ATP-sensitive potassium (KATP) channel cause neonatal diabetes (ND). This may be either transient or permanent and, in approximately 20% of patients, is associated with neurodevelopmental delay. In most patients, switching from insulin to oral sulfonylurea therapy improves glycemic control and ameliorates some of the neurological disabilities. Here, we review how KATP channel mutations lead to the varied clinical phenotype, how sulfonylureas exert their therapeutic effects, and why their efficacy varies with individual mutations.

Original publication

DOI

10.1016/j.tem.2017.02.003

Type

Journal article

Journal

Trends Endocrinol Metab

Publication Date

05/2017

Volume

28

Pages

377 - 387

Keywords

Blood Glucose, Diabetes Mellitus, Humans, Hypoglycemic Agents, Infant, Newborn, KATP Channels, Mutation, Sulfonylurea Compounds